Fingerprint
Dive into the research topics of 'Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study
Francesca Lombardi, Simone Belmonti, Massimiliano Fabbiani, Alberto Borghetti, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto
Research output: Contribution to journal › Article
2
Citations
(Scopus)